Pfizer reported a beat in second quarter earnings, with revenue of $14.7 billion and earnings per share of $0.78, exceeding Wall Street expectations. The company reaffirmed its 2025 revenue guidance of $61 billion to $64 billion, resulting in a higher stock trading premarket.

CEO Albert Bourla highlighted Pfizer’s strong execution and progress in advancing its R&D pipeline post-COVID. The company has been right-sizing its business after the pandemic, initiating cost-cutting efforts to achieve $4.5 billion in savings by year-end, including a $43 billion acquisition boosting its financials.

Pfizer raised its full-year 2025 earnings per share guidance by $0.10 to a range of $2.90 to $3.10, driven by a one-time $0.20 impact from a licensing deal with Chinese biotech 3SBio. CFO David Denton expressed confidence in delivering stronger results through the year, reinforcing the company’s strategic priorities.

Read more at Yahoo Finance: Pfizer beats in Q2 earnings, reaffirms 2025 outlook